A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for breast cancer patients. The hypothesis of this protocol is that the combined an active angiogenesis agent to chemotherapy could enhance the pathological responce rate and further benefit breast cancer patients.
Epistemonikos ID: ee7c6b77b63637db7efa4ab0af1c39ffa6225f21
First added on: May 11, 2024